ViGenCell wins ASCO oral slot with Phase 2 cell therapy data

ViGenCell has been selected to deliver an official oral presentation at this year’s American Society of Clinical Oncology annual meeting next month, becoming the first Korean company to do so regarding clinical studies of a cell therapy.

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.